Polydex Pharmaceuticals Stock Profit Margin
| POLXFDelisted Stock | USD 1.96 0.01 0.51% |
Polydex Pharmaceuticals fundamentals help investors to digest information that contributes to Polydex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Polydex Pink Sheet. The fundamental analysis module provides a way to measure Polydex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Polydex Pharmaceuticals pink sheet.
Polydex |
Polydex Pharmaceuticals Company Profit Margin Analysis
Polydex Pharmaceuticals' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Polydex Pharmaceuticals Profit Margin | (0.25) % |
Most of Polydex Pharmaceuticals' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Polydex Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, Polydex Pharmaceuticals has a Profit Margin of -0.2528%. This is 97.74% lower than that of the Pharmaceuticals sector and 98.9% lower than that of the Health Care industry. The profit margin for all United States stocks is 80.09% lower than that of the firm.
Polydex Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Polydex Pharmaceuticals' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Polydex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Polydex Pharmaceuticals by comparing valuation metrics of similar companies.Polydex Pharmaceuticals is currently under evaluation in profit margin category among its peers.
Polydex Fundamentals
| Return On Equity | -0.18 | |||
| Return On Asset | -0.0824 | |||
| Profit Margin | (0.25) % | |||
| Operating Margin | (0.22) % | |||
| Current Valuation | 2.23 M | |||
| Shares Outstanding | 3.43 M | |||
| Number Of Shares Shorted | 11 | |||
| Price To Earning | 12.33 X | |||
| Price To Book | 0.42 X | |||
| Price To Sales | 0.51 X | |||
| Revenue | 4.05 M | |||
| Gross Profit | 970.3 K | |||
| EBITDA | (568.16 K) | |||
| Cash And Equivalents | 870.3 K | |||
| Cash Per Share | 0.25 X | |||
| Total Debt | 301.49 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 5.88 X | |||
| Book Value Per Share | 1.44 X | |||
| Cash Flow From Operations | (238.54 K) | |||
| Short Ratio | 0.02 X | |||
| Earnings Per Share | (0.13) X | |||
| Number Of Employees | 21 | |||
| Beta | 0.33 | |||
| Market Capitalization | 2.23 M | |||
| Total Asset | 6.56 M | |||
| Retained Earnings | (19.53 M) | |||
| Working Capital | 2.12 M | |||
| Current Asset | 3.41 M | |||
| Current Liabilities | 1.28 M | |||
| Z Score | 1.4 |
About Polydex Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Polydex Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Polydex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Polydex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Polydex Pink Sheet
If you are still planning to invest in Polydex Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Polydex Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |